All Stories

  1. Association of superior vena cava syndrome with small cell lung cancer

    Article • Oncology in Clinical Practice, October 2025, VM Media SP. zo.o VM Group SK

    Dr Faruk TAS

  2. Clinical significances of variations in main hematological parameters at the time of diagnosis in patients with small cell lung cancer

    Article • Oncology in Clinical Practice, October 2025, VM Media SP. zo.o VM Group SK

    Dr Faruk TAS

  3. Associations of Increasing Serum Lactate Dehydrogenase Levels With Chemotherapy Responsiveness and Survival in Patients With Extensive Disease Small Cell Lung Cancer

    Article • American Journal of Therapeutics, September 2025, Wolters Kluwer Health

    Dr Faruk TAS

  4. Temozolomide After Excision of Lung Metastases in Patients With Melanoma

    Article • American Journal of Therapeutics, June 2025, Wolters Kluwer Health

    Dr Faruk TAS

  5. Sex Difference Has No Effect on Survival in Pancreatic Cancer

    Article • Indian Journal of Surgical Oncology, May 2025, Springer Science + Business Media

    Dr Faruk TAS

  6. Access to current medicines in the treatment of Turkish melanoma patients

    Article • Journal of Oncology Pharmacy Practice, May 2025, SAGE Publications

    Dr Faruk TAS

  7. Age-related Survival Declines in Turkish Patients with Cutaneous Melanoma: A Retrospective Analysis

    Article • Dermatology Practical & Conceptual, April 2025, Mattioli1885

    Dr Faruk TAS

  8. Effects of Home-Based Exercise Program on Chemotherapy-Induced Peripheral Neuropathy and Quality of Life

    Article • Cancer Nursing, March 2025, Wolters Kluwer Health

    Dr Faruk TAS

  9. Nivolumab-induced immune-mediated acute gastritis in a melanoma patient

    Article • Melanoma Research, March 2025, Wolters Kluwer Health

    Dr Faruk TAS

  10. Effects of Age, Gender, Histopathology, and Anatomical Location of the Lesion on BRAF Mutation in Turkish Cutaneous Melanoma Patients

    Article • Indian Journal of Surgery, March 2025, Springer Science + Business Media

    Dr Faruk TAS

  11. A Melanosis Patient with Primary Unknown Metastatic Melanoma: Successful Treatment with BRAF/MEK Inhibitors

    Article • Journal of the Scientific Society, February 2025, Wolters Kluwer Health

    Dr Faruk TAS

  12. CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER?

    Article • Sağlık Bilimlerinde İleri Araştırmalar Dergisi / Journal of Advanced Research in Health Sciences, February 2025, Istanbul University

    Dr Faruk TAS

  13. Brain metastases during follow-up of patients with resected cutaneous melanoma

    Article • Melanoma Research, February 2025, Wolters Kluwer Health

    Dr Faruk TAS

  14. Avoiding Cutaneous Melanoma Requires Proper Sun Protection and a Correspondingly High Level of Education: A Case Control Study

    Article • Journal of Cosmetic Dermatology, December 2024, Wiley

    Dr Faruk TAS

  15. Clinical significances of TTF-1, neuroendocrine (chromogranin, synaptophysin, CD56), and keratin (pancytokeratin, CK7, CK5/6) marker immunostaining in small cell lung cancer

    Article • Revista de Oncología, August 2024, Springer Science + Business Media

    Dr Faruk TAS

  16. FEMALE PATIENTS WITH SMALL CELL LUNG CANCER HAVE BETTER SURVIVAL THAN MALES WITH EXTENSIVE BUT NOT LIMITED DISEASE

    Article • Oncology Research and Treatment, July 2024, Karger Publishers

    Dr Faruk TAS

  17. Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer

    Article • Postgraduate Medicine, March 2024, Taylor & Francis

    Dr Faruk TAS

  18. Comorbidity in Small Cell Lung Cancer: Prognostic Impacts of Hypertension/Coronary Artery Disease, Diabetes Mellitus, and Chronic Obstructive Pulmonary Disease

    Article • Cancer Investigation, February 2024, Taylor & Francis

    Dr Faruk TAS

  19. A Modified H-index Calculated Using the Duration of Professional Experience and the Author's Significant Contribution to Publications

    Article • Cureus, January 2024, Springer Science + Business Media

    Dr Faruk TAS

  20. Timing of chemotherapy after diagnosis of small cell lung cancer

    Article • Journal of Chemotherapy, January 2024, Taylor & Francis

    Dr Faruk TAS

  21. Effect of Histological Subtype on Metastasis Distribution in Resected Cutaneous Melanoma

    Article • Indian Journal of Dermatology, January 2024, Medknow

    Dr Faruk TAS

  22. Primary tumor SUVmax and ratio of SUVmax to primary tumor size on pretreatment 18F-FDG-PET/CT scan in small cell lung cancer

    Article • Wiener klinische Wochenschrift, March 2023, Springer Science + Business Media

    Dr Faruk TAS

  23. Turkey's contribution to cancer publication: Expected quantity, unsatisfactory quality

    Article • Journal of Cancer Research and Therapeutics, January 2023, Medknow

    Dr Faruk TAS

  24. Diagnosing lung cancer at a younger age and with male dominance: Comparison of Turkish patients with United States patients

    Article • Journal of Cancer Research and Therapeutics, January 2023, Medknow

    Dr Faruk TAS

  25. Online public interest in smoking and lung cancer: A comparative study in Google Trends

    Article • Journal of Cancer Research and Therapeutics, January 2023, Medknow

    Dr Faruk TAS

  26. Melanoma publications do not increase as much as the incidence of melanoma in the last two decades

    Article • Journal of Cancer Research and Therapeutics, January 2023, Medknow

    Dr Faruk TAS

  27. Neither the presence nor the severity of hyponatremia affected the outcome of the patients with small cell lung cancer

    Article • Irish Journal of Medical Science (1971 -), October 2022, Springer Science + Business Media

    Dr Faruk TAS

  28. Intraabdominal splenosis due to traffic accident

    Article • Trauma, October 2022, SAGE Publications

    Dr Faruk TAS

  29. Ulceration vs Mitosis in Cutaneous Melanoma: which is Superior for Predicting Prognosis Across Clinical Stages?

    Article • Cancer Investigation, October 2022, Taylor & Francis

    Dr Faruk TAS

  30. Median Age of Cutaneous Melanoma Presentation in Turkey from a Single Tertiary Center Is Younger Than Other Western Countries

    Article • Indian Journal of Surgery, September 2022, Springer Science + Business Media

    Dr Faruk TAS

  31. Breast cancer patients are diagnosed at younger ages in Turkey: a comparative study

    Article • Irish Journal of Medical Science (1971 -), August 2022, Springer Science + Business Media

    Dr Faruk TAS

  32. Completion Lymph Node Dissection Is Unnecessary After Positive Sentinel Lymph Node in Melanoma — a Case Series Analysis

    Article • Indian Journal of Surgery, July 2022, Springer Science + Business Media

    Dr Faruk TAS

  33. Major Histotypes in Skin Melanoma: Nodular and Acral Lentiginous Melanomas Are Poor Prognostic Factors for Relapse and Survival

    Article • American Journal of Dermatopathology, July 2022, Wolters Kluwer Health

    Dr Faruk TAS

  34. Using Google as a Source of Information About Breast Cancer

    Article • Indian Journal of Surgery, June 2022, Springer Science + Business Media

    Dr Faruk TAS

  35. Trunk melanomas: no survival differences between lesion sites

    Article • Postgraduate Medicine, May 2022, Taylor & Francis

    Dr Faruk TAS

  36. Successful Treatment of a 92-Year-Old Classic Kaposi's Sarcoma Man With Ultra-Low Dose Oral Etoposide

    Article • Journal of Oncology Pharmacy Practice, February 2022, SAGE Publications

    Dr Faruk TAS

  37. Seasons Influence Diagnosis of Breast Cancer in Turkey

    Article • Indian Journal of Surgery, January 2022, Springer Science + Business Media

    Dr Faruk TAS

  38. Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences

    Article • Journal of Cancer Research and Therapeutics, January 2022, Medknow

    Dr Faruk TAS

  39. Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma

    Article • International Journal of Dermatology, October 2021, Wiley

    Dr Faruk TAS

  40. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: retrospective real‐life data

    Article • Dermatologic Therapy, September 2021, Wiley

    Dr Faruk TAS

  41. Digit melanomas are associated with poor prognostic factors and unfavorable survivals

    Article • Journal of Cosmetic Dermatology, August 2021, Wiley

    Dr Faruk TAS

  42. Larger Tumors Are Associated with Poorer Prognostic Factors in Cutaneous Melanoma

    Article • Indian Journal of Surgery, July 2021, Springer Science + Business Media

    Dr Faruk TAS

  43. Unknown Primary Metastatic Melanoma Presented with Extensive Subcutaneous Masses and Lymph Node Enlargements

    Article • Indian Journal of Surgery, July 2021, Springer Science + Business Media

    Dr Faruk TAS

  44. Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates

    Article • Journal of Cosmetic Dermatology, June 2021, Wiley

    Dr Faruk TAS

  45. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number

    Article • Japanese Journal of Clinical Oncology, March 2021, Oxford University Press (OUP)

    Dr Faruk TAS

  46. Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma

    Article • Journal of Cancer Research and Clinical Oncology, February 2021, Springer Science + Business Media

    Dr Faruk TAS

  47. Serum folate and vitamin B12 levels in cutaneous melanoma

    Article • Journal of Cosmetic Dermatology, January 2021, Wiley

    Dr Faruk TAS

  48. Limb melanomas: acral melanomas have worse survival

    Article • Journal of Dermatological Treatment, January 2021, Taylor & Francis

    Dr Faruk TAS

  49. Complementary and alternative medicine (CAM) in Turkish cutaneous melanoma patients: A prospective study from tertiary cancer center

    Article • Journal of Oncology Pharmacy Practice, January 2021, SAGE Publications

    Dr Faruk TAS

  50. Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.

    Article • Japanese Journal of Clinical Oncology, November 2020, Oxford University Press (OUP)

    Dr Faruk TAS

  51. Awareness on malignant melanoma and its prevention measures among Turkish cutaneous malignant melanoma patients: A tertiary cancer center experience

    Article • Dermatologic Therapy, October 2020, Wiley

    Dr Faruk TAS

  52. Google searching as an indicator of population's interest in melanoma: A comparative study in Google Trends

    Article • Dermatologic Therapy, October 2020, Wiley

    Dr Faruk TAS

  53. Multiple combinations of melanocytic and vascular endothelial markers enhances the detection rate of lymphovascular invasion in cutaneous melanoma

    Article • Journal of Cutaneous Pathology, September 2020, Wiley

    Dr Faruk TAS

  54. Serum 25-Hydroxyvitamin D Level Is Not Associated with Duration and Activity of Disease in Melanoma Patients

    Article • Nutrition and Cancer, June 2020, Taylor & Francis

    Dr Faruk TAS

  55. Paradox in melanoma

    Article • Melanoma Research, June 2020, Wolters Kluwer Health

    Dr Faruk TAS

  56. De Novo and Nevus-Associated Melanomas: Different Histopathologic Characteristics but Similar Survival Rates

    Article • Pathology & Oncology Research, June 2020, Springer Science + Business Media

    Dr Faruk TAS

  57. SEASONS INFLUENCE DIAGNOSIS AND OUTCOME OF CUTANEOUS MELANOMA

    Article • Dermatologic Therapy, May 2020, Wiley

    Dr Faruk TAS

  58. Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma

    Article • Journal of Oncology Pharmacy Practice, March 2020, SAGE Publications

    Dr Faruk TAS

  59. BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients

    Article • Dermatologic Therapy, February 2020, Wiley

    Dr Faruk TAS

  60. Cutaneous melanoma in vicenarians: Patients in their twenties and older patients show similar clinical behaviors and survival rates

    Article • Journal of Cosmetic Dermatology, January 2020, Wiley

    Dr Faruk TAS

  61. Trends in the characteristics of skin melanoma in accordance with time intervals: A single Turkish tertiary referral center experience

    Article • Journal of Cancer Research and Therapeutics, January 2020, Medknow

    Dr Faruk TAS

  62. Distichiasis in association with entropion in metastatic HER2‐positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy

    Article • The Breast Journal, November 2019, Wiley

    Dr Faruk TAS

  63. Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma

    Article • Annals of Plastic Surgery, October 2019, Wolters Kluwer Health

    Dr Faruk TAS

  64. Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?

    Article • Wiener klinische Wochenschrift, August 2019, Springer Science + Business Media

    Dr Faruk TAS

  65. The course of stage III melanoma in accordance with the severity of node involvement

    Article • Current Medical Research and Opinion, July 2019, Taylor & Francis

    Dr Faruk TAS

  66. Spitzoid cutaneous melanoma is associated with favorable clinicopathological factors and outcome

    Article • Journal of Cosmetic Dermatology, April 2019, Wiley

    Dr Faruk TAS

  67. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha

    Article • Cancer Chemotherapy and Pharmacology, April 2019, Springer Science + Business Media

    Dr Faruk TAS

  68. Cheek Cutaneous Melanomas

    Article • Annals of Plastic Surgery, April 2019, Wolters Kluwer Health

    Dr Faruk TAS

  69. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma

    Article • International Journal of Clinical Oncology, February 2019, Springer Science + Business Media

    Dr Faruk TAS

  70. Early and late relapses of cutaneous melanoma patients

    Article • Postgraduate Medicine, January 2019, Taylor & Francis

    Dr Faruk TAS

  71. Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients

    Article • Neoplasma, January 2019, AEPress, s.r.o.

    Dr Faruk TAS

  72. Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer

    Article • Biomolecules, December 2018, MDPI AG

    Dr Faruk TAS, Murat Serilmez

  73. Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma

    Article • Case Reports in Oncological Medicine, November 2018, Hindawi Publishing Corporation

    Dr Faruk TAS

  74. Relapse patterns in patients with local and regional cutaneous melanoma

    Article • Revista de Oncología, September 2018, Springer Science + Business Media

    Dr Faruk TAS

  75. Palpebral cutaneous melanomas: a review of 17 cases from a tertiary center

    Article • International Journal of Dermatology, August 2018, Wiley

    Dr Faruk TAS

  76. Clinical significance of serum leptin level in patients with gastric cancer

    Article • European Cytokine Network, June 2018, John Libbey Eurotext

    Dr Faruk TAS

  77. Widespread finger skin metastases of melanoma

    Article • Clinical Case Reports, January 2018, Wiley

    Dr Faruk TAS

  78. Acral Lentiginous Melanoma Is Associated with Certain Poor Prognostic Histopathological Factors but May Not be Correlated with Nodal Involvement, Recurrence, and a Worse Survival

    Article • Pathobiology, January 2018, Karger Publishers

    Dr Faruk TAS

  79. Neurotropism as a prognostic factor in cutaneous melanoma patients

    Article • Neoplasma, January 2018, AEPress, s.r.o.

    Dr Faruk TAS

  80. Anemia in Cutaneous Malignant Melanoma: Low Blood Hemoglobin Level is Associated with Nodal Involvement, Metastatic Disease, and Worse Survival

    Article • Nutrition and Cancer, December 2017, Taylor & Francis

    Dr Faruk TAS

  81. Digital clubbing as a first clinical presentation of pulmonary metastases in cutaneous melanoma

    Article • Postgraduate Medicine, November 2017, Taylor & Francis

    Dr Faruk TAS

  82. Significance of serum neural precursor cell‑expressed developmentally downregulated protein 9 in melanoma

    Article • Molecular and Clinical Oncology, November 2017, Spandidos Publications

    Dr Faruk TAS, Murat Serilmez

  83. Cutaneous Melanoma in Association With Ichthyosis Vulgaris

    Article • Journal of Pediatric Hematology/Oncology, November 2017, Wolters Kluwer Health

    Dr Faruk TAS, Dr Fatih Göktay

  84. Effect of biology on the outcome of female melanoma patients

    Article • Molecular and Clinical Oncology, October 2017, Spandidos Publications

    Dr Faruk TAS

  85. Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma

    Article • Molecular and Clinical Oncology, October 2017, Spandidos Publications

    Dr Faruk TAS

  86. Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival

    Article • Molecular and Clinical Oncology, October 2017, Spandidos Publications

    Dr Faruk TAS

  87. Plantar melanoma is associated with certain poor prognostic histopathological factors, but not correlated with nodal involvement, recurrence, and worse survival

    Article • Revista de Oncología, September 2017, Springer Science + Business Media

    Dr Faruk TAS

  88. Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients

    Article • Cancer Investigation, August 2017, Taylor & Francis

    Dr Faruk TAS

  89. Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome

    Article • Melanoma Research, August 2017, Wolters Kluwer Health

    Dr Faruk TAS

  90. Recurrence behavior in early-stage cutaneous melanoma

    Article • Melanoma Research, April 2017, Wolters Kluwer Health

    Dr Faruk TAS

  91. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma

    Article • Journal of Infection and Chemotherapy, April 2017, Elsevier

    Dr Faruk TAS

  92. Histological lymphovascular invasion is associated with nodal involvement, recurrence, and survival in patients with cutaneous malignant melanoma

    Article • International Journal of Dermatology, October 2016, Wiley

    Dr Faruk TAS

  93. Presence of histological regression as a prognostic factor in cutaneous melanoma patients

    Article • Melanoma Research, October 2016, Wolters Kluwer Health

    Dr Faruk TAS

  94. Clinical significance of serum claudin-1 levels in melanoma patients

    Article • Melanoma Research, August 2016, Wolters Kluwer Health

    Dr Faruk TAS

  95. Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma

    Article • BBA Clinical, June 2016, Elsevier

    Dr Faruk TAS

  96. Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients

    Article • Journal of Gastrointestinal Cancer, April 2016, Springer Science + Business Media

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  97. Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?

    Article • Biomedicine & Pharmacotherapy, February 2016, Elsevier

    Dr Faruk TAS

  98. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies

    Article • American Journal of Therapeutics, January 2016, Wolters Kluwer Health

    Dr Faruk TAS

  99. Zosteriform type in-transit metastasis of melanoma

    Article • International Journal of Microbiology Research, January 2016, Medknow

    Dr Faruk TAS

  100. Majority of the most-cited articles on cutaneous malignant melanoma are published in non-dermatology/melanoma specialized journals

    Article • Journal of Cancer Research and Therapeutics, January 2016, Medknow

    Dr Faruk TAS

  101. Clinical significance of serum caveolin-1 levels in melanoma patients

    Article • International Journal of Dermatology, June 2015, Wiley

    Dr Faruk TAS

  102. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients

    Article • Cancer Biomarkers, June 2015, IOS Press

    Dr Faruk TAS

  103. Exacerbation of psoriasis induced by interferon-alpha treatment for melanoma

    Article • Cutaneous and Ocular Toxicology, March 2015, Taylor & Francis

    Dr Faruk TAS

  104. Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer

    Article • Biomedicine & Pharmacotherapy, March 2015, Elsevier

    Dr Faruk TAS

  105. Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables

    Article • Biomedicine & Pharmacotherapy, February 2015, Elsevier

    Dr Faruk TAS

  106. tas f

    Article • Journal of Cancer Research and Therapeutics, January 2015, Medknow

    Dr Faruk TAS

  107. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer

    Article • Cytokine, January 2015, Elsevier

    Dr Faruk TAS

  108. Combination of Capecitabine and Phenytoin May Cause Phenytoin Intoxication

    Article • American Journal of Therapeutics, January 2015, Wolters Kluwer Health

    Dr Faruk TAS

  109. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer

    Article • Tumor Biology, November 2014, Springer Science + Business Media

    Dr Faruk TAS

  110. Clinical significance of serum M30 and M65 levels in patients with breast cancer

    Article • Biomedicine & Pharmacotherapy, October 2014, Elsevier

    Dr Faruk TAS

  111. Clinical significance of serum fibronectin and vitronectin levels in melanoma patients

    Article • Melanoma Research, October 2014, Wolters Kluwer Health

    Dr Faruk TAS

  112. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer

    Article • Molecular and Cellular Biochemistry, July 2014, Springer Science + Business Media

    Dr Faruk TAS

  113. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer

    Article • Tumor Biology, June 2014, Springer Science + Business Media

    Dr Faruk TAS

  114. Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy

    Article • Tumor Biology, May 2014, Springer Science + Business Media

    Dr Faruk TAS

  115. Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma

    Article • Tumor Biology, April 2014, Springer Science + Business Media

    Dr Faruk TAS

  116. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer

    Article • Tumor Biology, April 2014, Springer Science + Business Media

    Dr Faruk TAS

  117. Clinical significance of serum tenascin-c levels in epithelial ovarian cancer

    Article • Tumor Biology, April 2014, Springer Science + Business Media

    Dr Faruk TAS, Murat Serilmez

  118. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

    Article • Cancer Chemotherapy and Pharmacology, March 2014, Springer Science + Business Media

    Dr Faruk TAS

  119. Coagulation tests show significant differences in patients with breast cancer

    Article • Tumor Biology, March 2014, Springer Science + Business Media

    Dr Faruk TAS

  120. Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer

    Article • Tumor Biology, February 2014, Springer Science + Business Media

    Dr Faruk TAS

  121. Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer

    Article • Cancer Chemotherapy and Pharmacology, January 2014, Springer Science + Business Media

    Dr Faruk TAS, Murat Serilmez

  122. An analysis of the most-cited research papers on oncology: which journals have they been published in?

    Article • Tumor Biology, January 2014, Springer Science + Business Media

    Dr Faruk TAS

  123. Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer

    Article • Tumor Biology, December 2013, Springer Science + Business Media

    Dr Faruk TAS, Murat Serilmez

  124. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer

    Article • Tumor Biology, December 2013, Springer Science + Business Media

    Dr Faruk TAS, Murat Serilmez

  125. Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients

    Article • Tumor Biology, November 2013, Springer Science + Business Media

    Dr Faruk TAS

  126. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer

    Article • Tumor Biology, November 2013, Springer Science + Business Media

    Dr Faruk TAS, Murat Serilmez

  127. Clinical significance of serum M30 and M65 levels in melanoma

    Article • Melanoma Research, October 2013, Wolters Kluwer Health

    Dr Faruk TAS, Murat Serilmez

  128. Age is a prognostic factor affecting survival in lung cancer patients

    Article • Oncology Letters, September 2013, Spandidos Publications

    Dr Faruk TAS

  129. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

    Article • Cancer Chemotherapy and Pharmacology, June 2013, Springer Science + Business Media

    Dr Faruk TAS

  130. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma

    Article • Tumor Biology, June 2013, Springer Science + Business Media

    Dr Faruk TAS

  131. Clinical Significance of Coagulation Assays in Metastatic Pancreatic Adenocarcinoma

    Article • Journal of Gastrointestinal Cancer, June 2013, Springer Science + Business Media

    Dr Faruk TAS

  132. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival

    Article • Molecular and Clinical Oncology, May 2013, Spandidos Publications

    Dr Faruk TAS

  133. Clinical and Prognostic Significance of Coagulation Assays in Gastric Cancer

    Article • Journal of Gastrointestinal Cancer, March 2013, Springer Science + Business Media

    Dr Faruk TAS, Murat Serilmez

  134. Clinical and prognostic significance of coagulation assays in lung cancer

    Article • Respiratory Medicine, March 2013, Elsevier

    Dr Faruk TAS, Murat Serilmez

  135. Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy‑naive advanced non-small cell lung cancer

    Article • Oncology Letters, February 2013, Spandidos Publications

    Dr Faruk TAS

  136. Recurrent Gastric Cancer Presenting with Both Scrotal and Facial Skin Metastases: A Case Report

    Article • Journal of Gastrointestinal Cancer, February 2013, Springer Science + Business Media

    Dr Faruk TAS

  137. Clinical and Prognostic Significance of Coagulation Assays in Advanced Epithelial Ovarian Cancer

    Article • International Journal of Gynecological Cancer, February 2013, Wolters Kluwer Health

    Dr Faruk TAS

  138. Adrenocortical Carcinoma: Clinicopathological Features, Prognostic Factors and Outcome

    Article • Urologia Internationalis, January 2013, Karger Publishers

    Dr Faruk TAS

  139. Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma

    Article • ISRN Dermatology, January 2013, Hindawi Publishing Corporation

    Dr Faruk TAS

  140. Clinical and prognostic significance of coagulation assays in melanoma

    Article • Melanoma Research, October 2012, Wolters Kluwer Health

    Dr Faruk TAS

  141. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer

    Article • International Journal of Clinical Oncology, September 2012, Springer Science + Business Media

    Dr Faruk TAS

  142. Age-specific incidence ratios of lung cancer (LC) in Turkey: LC in older people is increasing

    Article • Archives of Gerontology and Geriatrics, September 2012, Elsevier

    Dr Faruk TAS

  143. Age-specific incidence ratios of colorectal cancer (CRC) in Turkey: CRC in older people is increasing

    Article • Archives of Gerontology and Geriatrics, September 2012, Elsevier

    Dr Faruk TAS

  144. Age-specific incidence ratios of breast cancer (BC) in Turkey: BC in older people is increasing

    Article • Archives of Gerontology and Geriatrics, July 2012, Elsevier

    Dr Faruk TAS

  145. The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia

    Article • Journal of Cancer Research and Clinical Oncology, February 2012, Springer Science + Business Media

    Dr Faruk TAS

  146. Factors Influencing the Hormone Receptor and HER2 Levels in Breast Cancer: A Population-Based Analysis

    Article • Onkologie, January 2012, Karger Publishers

    Dr Faruk TAS

  147. Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors

    Article • Journal of Oncology, January 2012, Hindawi Publishing Corporation

    Dr Faruk TAS

  148. Classic Kaposi′s sarcoma with colonic involvement: A rare presentation with successful treatment with oral etoposide

    Article • Journal of Cancer Research and Therapeutics, January 2012, Medknow

    Dr Faruk TAS

  149. Association of clinical and pathological variables with survival in thymoma

    Article • Medical Oncology, November 2011, Springer Science + Business Media

    Dr Faruk TAS

  150. Melanoma-assocıated hypopıgmentatıon ın assocıatıon wıth locoregıonal relapse of melanoma

    Article • Surgery, November 2011, Elsevier

    Dr Faruk TAS

  151. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non–Small-Cell Lung Cancer: A Phase II Study

    Article • Clinical Lung Cancer, September 2011, Elsevier

    Dr Faruk TAS

  152. The major stressful life events and cancer: stress history and cancer

    Article • Medical Oncology, April 2011, Springer Science + Business Media

    Dr Faruk TAS

  153. Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma

    Article • Oncology, January 2011, Karger Publishers

    Dr Faruk TAS

  154. Cardiac involvement in melanoma: A case report and review of the literature

    Article • Journal of Cancer Research and Therapeutics, January 2010, Medknow

    Dr Faruk TAS

  155. Statistical Interpretation of CA125 and Bcl-2 in Serum of Patients With Late Stage Ovarian Cancer

    Article • American Journal of Clinical Oncology, December 2008, Wolters Kluwer Health

    Dr Faruk TAS

  156. Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer

    Article • International Journal of Clinical Oncology, August 2008, Springer Science + Business Media

    Dr Faruk TAS

  157. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer

    Article • International Journal of Clinical Oncology, April 2008, Springer Science + Business Media

    Dr Faruk TAS

  158. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma

    Article • Medical Oncology, March 2008, Springer Science + Business Media

    Dr Faruk TAS

  159. The Role of Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 in Predicting Response to Chemotherapy in Patients with Advanced Nonsmall Cell Lung Cancer

    Article • Southern Medical Journal, March 2008, Southern Medical Association

    Dr Faruk TAS

  160. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer

    Article • Lung Cancer, February 2008, Elsevier

    Dr Faruk TAS

  161. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases

    Article • Medical Oncology, January 2008, Springer Science + Business Media

    Dr Faruk TAS

  162. Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer

    Article • Trials, January 2008, Springer Science + Business Media

    Dr Faruk TAS

  163. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer

    Article • Investigational New Drugs, December 2007, Springer Science + Business Media

    Dr Faruk TAS

  164. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer

    Article • Medical Oncology, November 2007, Springer Science + Business Media

    Dr Faruk TAS

  165. Temozolomide in combination with fotemustine in patients with metastatic melanoma

    Article • Cancer Chemotherapy and Pharmacology, October 2007, Springer Science + Business Media

    Dr Faruk TAS

  166. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma

    Article • Lung Cancer, July 2007, Elsevier

    Dr Faruk TAS

  167. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer

    Article • Cancer Chemotherapy and Pharmacology, June 2007, Springer Science + Business Media

    Dr Faruk TAS

  168. Serum IL-8 and IL-12 levels in breast cancer

    Article • Medical Oncology, June 2007, Springer Science + Business Media

    Dr Faruk TAS

  169. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

    Article • Medical Oncology, June 2007, Springer Science + Business Media

    Dr Faruk TAS

  170. Pattern and Outcome of admission to a medical oncology inpatient service

    Article • Journal of Cancer Education, June 2007, Springer Science + Business Media

    Dr Faruk TAS

  171. Macrophage Migration Inhibitory Factor in Cancer

    Article • Cancer Investigation, January 2007, Taylor & Francis

    Dr Faruk TAS

  172. Sentinel lymph node biopsy for the staging of anal melanoma: Report of two cases

    Article • Annals of Nuclear Medicine, November 2006, Springer Science + Business Media

    Dr Faruk TAS

  173. Increased sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives

    Article • Cancer Genetics and Cytogenetics, November 2006, Elsevier

    Dr Faruk TAS

  174. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients

    Article • Melanoma Research, October 2006, Wolters Kluwer Health

    Dr Faruk TAS

  175. Penile metastasis of cutaneous malignant melanoma: a true hematogenous spread?

    Article • Melanoma Research, June 2006, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  176. Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung Cancer

    Article • Cancer Investigation, January 2006, Taylor & Francis

    Dr Faruk TAS

  177. The Value of Serum bcl-2 Levels in Advanced Epithelial Ovarian Cancer

    Article • Medical Oncology, January 2006, Springer Science + Business Media

    Dr Faruk TAS

  178. Intermediate Dose Interferon Alpha in Adjuvant Treatment for High-Risk Melanoma: A Single Institution's Experience

    Article • Medical Oncology, January 2006, Springer Science + Business Media

    Dr Faruk TAS

  179. Serum Vascular Endothelial Growth Factor (VEGF) and Bcl-2 Levels in Advanced Stage Non-Small Cell Lung Cancer

    Article • Cancer Investigation, January 2006, Taylor & Francis

    Dr Faruk TAS

  180. Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial

    Article • Melanoma Research, December 2005, Wolters Kluwer Health

    Dr Faruk TAS

  181. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients

    Article • Acta Oncologica, March 2005, Taylor & Francis

    Dr Faruk TAS

  182. Oxidative Stress in Breast Cancer

    Article • Medical Oncology, January 2005, Springer Science + Business Media

    Dr Faruk TAS

  183. Serum Levels of Leptin and Proinflammatory Cytokines in Advanced-Stage Non-Small Cell Lung Cancer

    Article • Medical Oncology, January 2005, Springer Science + Business Media

    Dr Faruk TAS

  184. Serum Matrix Metalloproteinase-3 and Tissue Inhibitor of Metalloproteinase-1 in Patients with Malignant Melanoma

    Article • Medical Oncology, January 2005, Springer Science + Business Media

    Dr Faruk TAS

  185. The Value of Serum Bcl-2 Levels in Advanced Lung Cancer Patients

    Article • Medical Oncology, January 2005, Springer Science + Business Media

    Dr Faruk TAS

  186. Apoptosis of Lymphocytes in Peripheral Blood of Patients with Melanoma

    Article • Medical Oncology, January 2005, Springer Science + Business Media

    Dr Faruk TAS

  187. The Value of Serum Levels of IL-6, TNF-alpha, and Erythropoietin in Metastatic Malignant Melanoma: Serum IL-6 Level Is a Valuable Prognostic Factor at Least as Serum LDH in Advanced Melanoma

    Article • Medical Oncology, January 2005, Springer Science + Business Media

    Dr Faruk TAS

  188. Serum bcl-2 and survivin levels in melanoma

    Article • Melanoma Research, December 2004, Wolters Kluwer Health

    Dr Faruk TAS

  189. Clinical Value of Protein S100 and Melanoma-Inhibitory Activity (MIA) in Malignant Melanoma

    Article • American Journal of Clinical Oncology, June 2004, Wolters Kluwer Health

    Dr Faruk TAS

  190. MASSIVE AND ISOLATED METASTASES TO SPLEEN OF UVEAL MALIGNANT MELANOMA

    Article • Retina, February 2004, Wolters Kluwer Health

    Dr Faruk TAS

  191. Second-Line Docetaxel and Gemcitabine Combination Chemotherapy in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: A Phase II Trial

    Article • Medical Oncology, January 2004, Springer Science + Business Media

    Dr Faruk TAS

  192. Granulosa Cell Tumor of the Ovary

    Article • American Journal of Clinical Oncology, October 2003, Wolters Kluwer Health

    Dr Faruk TAS

  193. Retrovesical Soft-Tissue Metastasis of Malignant Thymoma

    Article • American Journal of Clinical Oncology, August 2003, Wolters Kluwer Health

    Dr Faruk TAS

  194. Correspondence

    Article • Clinical Oncology, May 2003, Elsevier

    Dr Faruk TAS

  195. Adjuvant Intraperitoneal Chemotherapy With Cisplatinum, Mitoxantrone, 5-Fluorouracil, and Calcium Folinate in Patients With Gastric Cancer

    Article • American Journal of Clinical Oncology, December 2002, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  196. Anemia in Oncology Practice

    Article • American Journal of Clinical Oncology, August 2002, Wolters Kluwer Health

    Dr Faruk TAS

  197. Safety of Paclitaxel in a Patient with Ovarian Cancer and Hyperbilirubinemia Due to Rotor's Syndrome

    Article • Gynecologic Oncology, May 2002, Elsevier

    Dr Faruk TAS

  198. Prognostic Role of nm23 Gene Expression in Patients With Ovarian Cancer

    Article • American Journal of Clinical Oncology, April 2002, Wolters Kluwer Health

    Dr Faruk TAS

  199. Prognostic Factors in Pancreatic Carcinoma

    Article • American Journal of Clinical Oncology, December 2001, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  200. Treatment of Aggressive Non-Hodgkin’s Lymphoma With Dose-Intensified Epirubicin in Combination of Cyclophosphamide, Vincristine, and Prednisone (CEOP-100)

    Article • American Journal of Clinical Oncology, December 2001, Wolters Kluwer Health

    Dr Faruk TAS

  201. Stevens-Johnson Syndrome in a Patient Receiving Anticonvulsant Therapy During Cranial Irradiation

    Article • American Journal of Clinical Oncology, August 2001, Wolters Kluwer Health

    Dr Faruk TAS

  202. Serum Lactate Dehydrogenase Levels at Presentation Predict Outcome of Patients With Limited-Stage Small-Cell Lung Cancer

    Article • American Journal of Clinical Oncology, August 2001, Wolters Kluwer Health

    Dr Faruk TAS

  203. Measurement of Serum CA 19-9 May Be More Valuable Than CEA in Prediction of Recurrence in Patients With Gastric Cancer

    Article • American Journal of Clinical Oncology, April 2001, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  204. Angiogenesis and p53 Protein Expression in Breast Cancer

    Article • American Journal of Clinical Oncology, December 2000, Wolters Kluwer Health

    Dr Faruk TAS

  205. Multiple Primary Neoplasms at a Single Institution

    Article • American Journal of Clinical Oncology, August 2000, Wolters Kluwer Health

    Dr Faruk TAS

  206. Celsite® port and catheter as an intraperitoneal access device in the treatment of ovarian cancer

    Article • Journal of Surgical Oncology, July 2000, Wiley

    Dr Faruk TAS

  207. Serum levels of the soluble adhesion molecules in patients with malignant melanoma

    Article • Pathology & Oncology Research, March 2000, Springer Science + Business Media

    Dr Faruk TAS

  208. The Roles of Chemotherapy and Surgery in Gastric Carcinoma and the Influence of Prognostic Factors on Survival

    Article • American Journal of Clinical Oncology, February 2000, Wolters Kluwer Health

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan

  209. Celsite� port and catheter as an intraperitoneal access device in the treatment of ovarian cancer

    Article • Journal of Surgical Oncology, January 2000, Wiley

    Dr Faruk TAS

  210. Factors Influencing the Distribution of Metastases and Survival in Extensive Disease Small Cell Lung Cancer

    Article • Acta Oncologica, January 1999, Taylor & Francis

    Dr Faruk TAS

  211. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5‐fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

    Article • Cancer, December 1998, Wiley

    Dr Faruk TAS, Prof Dr Faruk Nuri Aykan